On December 27, the US Food and Drug Administration approved nivolumab and hyaluronidase-nvhy for subcutaneous injection across approved adult, solid tumor nivolumab indications as monotherapy, monotherapy maintenance following completion of nivolumab plus ipilimumab combination therapy, or in combination with chemotherapy or cabozantinib.
For more information, read the FDA announcement and the Bristol Myers Squibb press release.
Posted on 1/2/2025
